DEM BioPharma
- Biotech or pharma, therapeutic R&D
DEM Biopharma is pioneering the next generation of Cancer Therapeutics. Our proprietary functional genomics platform identifies novel targets for solid tumors. Our lead program, DEM301, is an antibody-drug conjugate (ADC) targeting a novel extracellular protein that is over expressed in gastrointestinal and other malignancies.
Address
CambridgeMassachusetts
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}